Professor Chris Packard
Prof. Chris Packard holds an Honorary Professorship of Vascular Biochemistry at the University of Glasgow. Over his career, Professor Packard has focussed on two aspects of atherosclerosis research, lipoprotein metabolism and how it is affected by diets and drugs, and large-scale clinical trials of lipid lowering agents. He is acknowledged as one of the leading researchers in the world in this field.
Prof Packard has published widely on the kinetics of apolipoprotein B and apolipoprotein A metabolism. Key contributions include evaluation of the role of the LDL receptor in vivo, the discovery of metabolic channelling in the apoB lipoprotein delipidation cascade, and the formulation of models to explain the generation of small, dense LDL.
In this episode we discuss:
- Understanding systems biomarkers and independently causal factors
- Atherosclerosis development
- Markers of risk: LDL-C, ApoB, non-HDL-C, etc.
- What do we know about Lp(a) currently?
- What is the utility (and limitation) of a CAC score?
- Cholesterol transport vs. LDL-receptor upregulation as targets for treatment
- Is HDL fading from focus?
- The "lower is better" paradigm for LDL-C
- The LDL/old age "paradox"
- LDL: Low-density lipoprotein
- LDL-C: The cholesterol content of LDL particles.
- ApoB: ApolipoproteinB - a protein structure found on various lipoproteins including LDL, IDL, VLDL and chylomicrons. But is not found on HDL particles. As one ApoB is found on each of those artherogentic particles, it gives a measure of the concentration of atherogenic lipoproteins in the blood.
- ApoA: Apolipoprotein A is a protein structure found on high-density lipoproteins (HDL). Chylomicrons secreted from intestinal cells also contain ApoA, but it is quickly transferred to HDL in the bloodstream.
- Non-HDL-C: The measurement of total cholesterol minus high density lipoprotein cholesterol.
- CRP: C-reactive protein - a protein that is elevated in the blood in response to inflammation. Used as a marker of inflammation.
- Troponin I: Cardiac troponin I is presented in cardiac muscle tissue. Cardiac troponin is a specific marker of myocardial injury and an independent predictor of cardiovascular mortality in patients with and without cardiovascular disease
- WOSCOPS: West of Scotland Coronary Prevention Study - a trial of statin-based low-density lipoprotein (LDL) cholesterol-lowering therapy in men ages 45 to 64 years with raised serum cholesterol concentrations.
- GWAS: A genome-wide association study (GWAS) is an observational study of a genome-wide set of genetic variants in different individuals to see if any variant is associated with a trait.
Links & Resources
- Sigma Statment Series (Written Format)
- Packard et al., 2018 - LDL cholesterol: How low to go?
- Ference et al., 2019 - Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease
- Boren et al., 2020 - Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
- Related Podcast Episodes:
- #315: Samia Mora, MD – Lipids, Lipoproteins & Atherosclerosis
- #317: Understanding Diet & Heart Disease Risk
- #321: Dave Feldman & Alan Flanagan – Debating LDL Causality & the “Lipid Triad”
- #343: Understanding Causality in Nutrition Science
- #371: Dietary Cholesterol – Are Eggs & Cholesterol-rich Foods a Cause for Concern?
Support the Podcast
If you regularly enjoy listening to Sigma Nutrition Radio and you'd like to take your support even further, then you can officially support the podcast by either making a one-time donation or via a recurring payment. If you wish to do so then you can do so here.
Thank you for considering!